Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors | OncLive

Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

November 16, 2017

Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

A phase II trial in patients with carcinoid and pancreatic NETs showed that treatment with cabozantinib was associated with objective tumor responses, as well as encouraging progression-free survival.

Chan says there is ongoing work to evaluate cabozantinib in a larger trial.


x